Sunak's first budget tackles pharma R&D as well as coronavir...

In his first budget as UK chancellor, Rishi Sunak’s main focus was to prepare the country for the impact of coronavirus – but there were other pharma-friendly measures in there too.

Takeda's Ninlaro falls short in first line multiple myeloma

Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.

BMS backs record $600m European venture fund closed by LSP

Stem cell transplant eradicates HIV in second patient

Shionogi and Tetra expand partnership ahead of Alzheimer's t...

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

Charities bankroll coronavirus drug hunt, as outbreak hits e...